Crm1 knockdown by specific small interfering RNA reduces cell proliferation and induces apoptosis in head and neck cancer cell lines

Head and neck squamous cell carcinoma (HNSCC) is the most common and most aggressive type of head and neck cancer.Current approaches for the treatment of HNSCC are not sufficient to increase the patient survival or to reduce the high recurrencerate. Consequently, there is a need to explore the molecular characteristics of this cancer in order to discover potential therapeutictarget molecules. The overexpression of chromosome region maintenance 1 (Crm1), responsible for the transport of different classes ofmacromolecules from the nuclear membrane to the cytoplasm, in various cancer cells has made it an attractive target molecule in cancerresearch. It has been reported that transcription factors, which are the target cargo proteins of Crm1, have critical roles in regulatingintracellular processes via their expression levels and functions, which in turn are regulated by the cell cycle and signaling proteins.Previous findings show that head and neck cancer cells overexpress Crm1 and that these cells become highly dependent on Crm1function. The results of this study show that after decreasing Crm1 expression levels in HNSCC cells through either treatment withspecific Crm1 RNA interference (siRNA) or the selective Crm1 inhibitor leptomycin B (LMB), cell viability, proliferation, migration,and wound-healing abilities decreased, suppressing tumorigenic properties through the induction of apoptosis. Crm1 is a powerfuldiagnostic biomarker because of its central role in cancerogenesis, and it has a high potential for the development of targeted Crm1molecules or synthetic agents, such as LMB, as well as for the improvement of the clinical features in head and neck cancer.

PDF

___

Bender O, Gunduz M, Cigdem S, Hatipoglu OF, Acar M, Kaya M, Grenman R, Gunduz E, Ugur KS (2018). Functional analysis of ESM1 by siRNA knockdown in primary and metastatic head and neck cancer cells. J Oral Pathol Med 47: 40-47.
Brodie KM, Henderson BR (2012). Characterization of BRCA1 protein targeting, dynamics, and function at the centrosome. A role for the nuclear export signal, CRM1, and Aurora A kinase. J Biol Chem 287: 7701-7716.
Chan CY, Lien CH, Lee MF, Huang CY (2016). Quercetin suppresses cellular migration and invasion in human head and neck squamous cell carcinoma (HNSCC). Biomedicine (Taipei) 6: 15.
Chan KS, Wong CH, Huang YF, Li HY (2010). Survivin withdrawal by nuclear export failure as a physiological switch to commit cells to apoptosis. Cell Death Dis 1: e57.
Daelemans D, Afonina E, Nilsson J, Werner G, Kjems J, De Clercq E, Pavlakis GN, Vandamme AM (2002). A synthetic HIV-1 Rev inhibitor interfering with the CRM1-mediated nuclear export. P Natl Acad Sci USA 99: 14440-14445.
Easty D, Easty G, Carter R, Monaghan P, Butler L (1981). Ten human carcinoma cell lines derived from squamous carcinomas of the head and neck. Br J Cancer 43: 772-785.
Fukuda M, Asano S, Nakamura T, Adachi M, Yoshida M, Yanagida M, Nishida E (1997). CRM1 is responsible for intracellular transport mediated by the nuclear export signal. Nature 390: 308-311.
Fung HY, Chook YM (2014). Atomic basis of CRM1-cargo recognition, release and inhibition. Semin Cancer Biol 27: 52- 61.
Henderson BR (2000). Nuclear cytoplasmic shuttling of APC regulates beta catenin subcellular localization and turnover. Nat Cell Biol 2: 653-660.
Ishizawa J, Kojima K, Hail N Jr, Tabe Y, Andreeff M (2015). Expression, function, and targeting of the nuclear exporter chromosome region maintenance 1 (CRM1) protein. Pharmacol Ther 153: 25-35.
Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ (2009). Cancer statistics. CA Cancer J Clin 59: 225-249.
Kaomongkolgit R (2013). Alpha-mangostin suppresses MMP-2 and MMP-9 expression in head and neck squamous carcinoma cells. Odontology 101: 227-232.
Kau TR, Schroeder F, Ramaswamy S, Wojciechowski CL, Zhao JJ, Roberts TM, Clardy J, Sellers WR, Silver PA (2003). A chemical genetic screen identifies inhibitors of regulated nuclear export of a Forkhead transcription factor in PTEN-deficient tumor cells. Cancer Cell 4: 463-476.
Kau TR, Way JC, Silver PA (2004). Nuclear transport and cancer: from mechanism to intervention. Nat Rev Cancer 4: 106-117.
Kudo N, Khochbin S, Nishi K, Kitano K, Yanagida M, Yoshida M, Horinouchi S (1997). Molecular cloning and cell cycle dependent expression of mammalian CRM1, a protein involved in nuclear export of proteins. J Biol Chem 272: 29742-29751.
Kudo N, Matsumori N, Taoka H, Fujiwara D, Schreiner, EP, Wolff B, Yoshida M, Horinouchi S (1999). Leptomycin B inactivates CRM1/exportin 1 by covalent modification at a cysteine residue in the central conserved region. P Natl Acad Sci USA 96: 9112-9117.
Kuusisto HV, Wagstaff KM, Alvisi G, Roth DM, Jans DA (2011). Global enhancement of nuclear localization-dependent nuclear transport in transformed cells. FASEB J 26: 1181-1193.
Lange MJ, Lasiter JC, Misfeldt ML (2009). Toll-like receptors in tonsillar epithelial cells. Int J Pediatr Otorhinolaryngol 73: 613-621.
Lin CJ, Grandis JR, Carey TE, Gollin SM, Whiteside TL, Koch WM, Ferris RL, Lai SY (2007). Head and neck squamous cell carcinoma cell lines: established models and rationale for selection. Head Neck 29: 163-188.
Liu X, Chong Y, Liu H, Han Y, Niu M (2016). CRM1 inhibitor S109 suppresses cell proliferation and induces cell cycle arrest in renal cancer cells. Korean J Physiol Pharmacol 20: 161-168.
Mao L, Hong WK, Papadimitrakopoulou VA (2004). Focus on head and neck cancer. Cancer Cell 5: 311-316.
Mariano AR, Colombo E, Luzi L, Martinelli P, Volorio S, Bernard L, Meani N, Bergomas R, Alcalay M, Pelicci PG (2006). Cytoplasmic localization of NPM in myeloid leukemias is dictated by gain of function mutations that create a functional nuclear export signal. Oncogene 25: 4376-4380.
Maushagen R, Reers S, Pfannerstill AC, Hahlbrock A, Stauber R, Rahmanzadeh R, Rades D, Pries R, Wollenberg B (2016). Effects of paclitaxel on permanent head and neck squamous cell carcinoma cell lines and identification of anti-apoptotic caspase 9b. J Cancer Res Clin Oncol 142: 1261-1271.
Newlands ES, Rustin GJ, Brampton MH (1996). Phase I trial of elactocin. Br J Cancer 74: 648-649.
Nguyen KT, Holloway MP, Altura RA (2012). The XPO1 nuclear export protein in normal development and disease. Int J Biochem Mol Biol 3: 137-151.
Noske A, Weichert W, Niesporek S, Roske A, Buckendahl AC, Koch I, Sehouli J, Dietel M, Denkert C (2008). Expression of the nuclear export protein chromosomal region maintenance/ exportin 1/Xpo1 is a prognostic factor in human ovarian cancer. Cancer 112: 1733-1743.
Sakakibara K, Saito N, Sato T, Suzuki A, Hasegawa Y, Friedman JM, Kufe DW, Vonhoff DD, Iwami T, Kawabe T (2011). CBS9106 is a novel reversible oral CRM1 inhibitor with CRM1 degrading activity. Blood 118: 3922-3931.
Santiago A, Li D, Zhao LY, Godsey A, Liao D (2013). p53 SUMOylation promotes its nuclear export by facilitating its release from the nuclear export receptor CRM1. Mol Biol Cell 24: 2739-2752.
Saussez S, Decaestecker C, Mahillon V, Cludts S, Capouillez A, Chevalier D, Vet HK, André S, Toubeau G, Leroy X et al. (2008). Galectin-3 upregulation during tumor progression in head and neck cancer. Laryngoscope 118: 1583-1590.
Shao WY, Yang YL, Yan H, Huang Q, Liu KJ, Zhang S (2017). Phenethyl isothiocyanate suppresses the metastasis of ovarian cancer associated with the inhibition of CRM1-mediated nuclear export and mTOR-STAT3 pathway. Cancer Biol Ther 18: 26-35.
Sheikh Ali MA, Gunduz M, Nagatsuka H, Gunduz E, Cengiz B, Fukushima K, Beder LB, Demircan K, Fujii M, Yamanaka N et al. (2008). Expression and mutation analysis of epidermal growth factor receptor in head and neck squamous cell carcinoma. Cancer Sci 99: 1589-1594.
Shen A, Wang Y, Zhao Y, Zou L, Sun L, Cheng C (2009). Expression of CRM1 in human gliomas and its significance in p27 expression and clinical prognosis. Neurosurgery 65: 153-159.
Siegel R, Ma J, Zou Z, Jemal A (2014). Cancer statistics, 2014. CA Cancer J Clin 64: 9-29.
Stell PM (1989). Survival times in end-stage head and neck cancer. Eur J Surg Oncol 15: 407-410.
Tai YT, Landesman Y, Acharya C, Calle Y, Zhong MY, Cea M, Tannenbaum D, Cagnetta A, Reagan M, Munshi AA et al. (2014). CRM1 inhibition induces tumor cell cytotoxicity and impairs osteoclastogenesis in multiple myeloma: molecular mechanisms and therapeutic implications. Leukemia 28: 155- 165.
Takenaka Y, Fukumori T, Yoshii T, Oka N, Inohara H, Kim HR, Bresalier RS, Raz A (2004). Nuclear export of phosphorylated galectin-3 regulates its antiapoptotic activity in response to chemotherapeutic drugs. Mol Cell Biol 24: 4395-4406.
Tamura S, Shiomi A, Kaneko M, Ye Y, Yoshida M, Yoshikawa M, Kimura T, Kobayashi M, Murakami N (2009). New Revexport inhibitor from Alpinia galanga and structure-activity relationship. Bioorg Med Chem Lett 19: 2555-2557.
Turner JG, Dawson J, Sullivan DM (2011). CRM1-mediated nuclear export of proteins and drug resistance in cancer. Curr Med Chem 15: 2648-2655.
Turner JG, Dawson J, Sullivan DM (2012). Nuclear export of proteins and drug resistance in cancer. Biochem Pharmacol 83: 1021- 1032.
van der Watt PJ, Leaner VD (2011). The nuclear exporter, Crm1, is regulated by NFY and Sp1 in cancer cells and repressed by p53 in response to DNA damage. Biochim Biophys Acta 1809: 316- 326.
van der Watt PJ, Maske CP, Hendricks DT, Parker MI, Denny L, Govender D, Birrer MJ, Leaner VD (2009). The Karyopherin proteins, Crm1 and Karyopherin β1, are overexpressed in cervical cancer and are critical for cancer cell survival and proliferation. Int J Cancer 124: 1829-1840.
van der Watt PJ, Zemanay W, Govender D, Hendricks DT, Parker MI, Leaner VD (2014). Elevated expression of the nuclear export protein, Crm1 (exportin 1), associates with human oesophageal squamous cell carcinoma. Oncol Rep 32: 730-738.
Wilken B, Veena MS, Wang MB, Srivatsan ES (2011). Curcumin: A review of anti-cancer properties and therapeutic activity in head and neck squamous cell carcinoma. Mol Cancer 10: 12.
Wolff B, Sanglier JJ, Wang Y (1997). Leptomycin B is an inhibitor of nuclear export: inhibition of nucleo-cytoplasmic translocation of the human immunodeficiency virus type 1 (HIV-1) Rev protein and Rev-dependent mRNA. Chem Biol 4: 139-147.
Yang X, Cheng L, Yao L, Ren H, Zhang S, Min X, Chen X, Zhang J, Li M (2014). Involvement of chromosome region maintenance 1 (CRM1) in the formation and progression of esophageal squamous cell carcinoma. Med Oncol 31: 155.
Yao Y, Dong Y, Lin F, Zhao H, Shen Z, Chen P, Sun YJ, Tang LN, Zheng SE (2009). The expression of CRM1 is associated with prognosis in human osteosarcoma. Oncol Rep 21: 229-235.
Yashiroda Y, Yoshida M (2003). Nucleo-cytoplasmic transport of proteins as a target for therapeutic drugs. Curr Med Chem 10: 741-748.
Yoshii T, Fukumori T, Honjo Y, Inohara H, Kim HR, Raz A (2002). Galectin-3 phosphorylation is required for its anti-apoptotic function and cell cycle arrest. J Biol Chem 277: 6852-6857.
Zhou F, Qiu W, Yao R, Xiang J, Sun X, Liu S, Lv J, Yue L (2013). CRM1 is a novel independent prognostic factor for the poor prognosis of gastric carcinomas. Med Oncol 30: 726.